Empagliflozin's Effect on Micro RNA150-5p Expression in Individuals with Diastolic Dysfunction of the Left Ventricle in Type 2 Diabetes Mellitus

Background: Type 2 Diabetes Mellitus (T2DM) is one of the most prevalent metabolic diseases characterized by persistent hyperglycemia, and heart failure can be a common comorbidity and fatal complication of diabetes mellitus. An early sign of diabetic heart disease is left ventricular diastolic dysfunction, and microRNA dysregulation was one of the pathogenic mechanisms behind left ventricular diastolic dysfunction.
Aims: To investigate the potential effect of Empagliflozin on genetic modulation (Micro RNA150-5P).
Method: This is a single-center, cross-sectional, descriptive observational research. Specialist cardiologists recruited sixty individual T2D and left ventricular diastolic dysfunctions at AL-Diwaniyah Teaching Hospital, and the amount of RNA was quantified. The total RNA was extracted using Trizol reagent (Genaid, Korea), and the manufacturer's instructions to Add the RT-qPCR Syber master script were followed when performing the primer amplification. (Add Bio, Korea)
Result: Empagliflozin induces a considerable dawn regulation of miR-150-5p in left ventricular diastolic dysfunction, indicating that empagliflozin negatively affects microRNA 150-5p in diabetic patients with LVDD.
Conclusion: Empagliflozin causes a decrease in the expression of micro RNA in diabetic patients with left ventricular diastolic dysfunction, and this effect is statistically significant compared to metformin treatment.